NILM pap slides from women 30 years of age and older with positive high-risk HPV DNA: Focused rescreening prior to report issuance, an enhanced quality control measure

American Journal of Clinical Pathology

Volumn 141, Issue 4, 2014, Pages 494-500

  Cormier, Karen ^a   Schaaf, Michael ^a   Hamilton, Stephanie ^a   Tickman, Ronald J ^a   Perez Reyes, Nuria ^a   Sturgis, Charles D ^a,b  

^a CellNetix Pathology and Laboratories   (United States)

^b Providence Regional Medical Center   (United States)

Author keywords

CLIA 88; High risk HPV DNA; Negative for intraepithelial lesion (NILM); Pap smears; Quality control

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOTECHNOLOGIST; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LABORATORY DIAGNOSIS; LAW; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RESCREENING; RETROSPECTIVE STUDY; SQUAMOUS CELL; STUDY DESIGN; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR KIT; WART VIRUS; CLIA '88; COLPOSCOPY; HIGH-RISK HPV DNA; MIDDLE AGED; NEGATIVE FOR INTRAEPITHELIAL LESION (NILM); PAP SMEARS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; VIROLOGY;

CLIA '88; HIGH-RISK HPV DNA; NEGATIVE FOR INTRAEPITHELIAL LESION (NILM); PAP SMEARS; QUALITY CONTROL;

ADULT; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; QUALITY CONTROL; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84899492863     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP98ENFCNOKVAE     Document Type: Article

References (21)

1. Clinical Laboratory Improvement Amendments of 1988: final rule. Federal Register. 1992;57:7001-7186.
2. Krieger PA, Cohen T, Naryshkin S. A practical guide to Papanicolaou smear rescreens: how many slides must be reevaluated to make a statistically valid assessment of screening performance? Cancer. 1998;84:130-137. (Pubitemid 28299754)
3. Renshaw AA. A practical problem with calculating the false-negative rate of Papanicolaou smear interpretation by rescreening negative cases alone. Cancer. 1999;87:351-353. (Pubitemid 30016606)
4. Lee BC, Lam SY, Walker T. Comparison of false negative rates between 100% rapid review and 10% random full rescreening as internal quality control methods in cervical cytology screening. Acta Cytol. 2009;53:271-276.
5. Utagawa ML, Shirata NK, Mattosinho de Castro Ferraz Mda G, et al. Performance of 3 methods for quality control of gynecologic cytology diagnoses. Acta Cytol. 2008;52:439-444.
6. Djemli A, Khetani K, Case BW, et al. Correlation of cytotechnologists' parameters with their performance in rapid prescreening of Papanicolaou smears. Cancer. 2006;108:306-310. (Pubitemid 44583709)
7. Ge Y, Smith D, Schwartz MR, et al. Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population. Cancer. 2009;117:326-332.
8. Massad LS, Einstine MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829-846.
9. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-542.
10. Sturgis CD, Schaaf MR, Tickman RJ. Focused rescreening of NILM Pap slides from women 2 30 years of age with positive high risk HPV DNA: an enhanced quality control measure. Diagn Cytopathol. 2013;41:399-403.
11. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113:595-600.
12. Thrall MJ, Russell DK, Facik MS, et al. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. Am J Clin Pathol. 2010;133:894-898.
13. Zhao C, Elishaev E, Yuan K, et al. Very low human papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests. Cancer. 2007;111:292-297.
14. Bansal M, Austin RM, Zhao C. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test sampled from women 30 and older. Gynecol Oncol. 2009;115:257-261.
15. Walboomers JM, De Roda Husman AM, Snijders PJ, et al. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol. 1995;48:728-732.
16. Clary KM, Davey DD, Naryshkin S, et al. The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations before sign-out, and turnaround time in gynecologic cytology quality assurance: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference Working Group 1. Arch Pathol Lab Med. 2013;137:164-174.
17. Brainard JA, Birdsong GG, Elsheikh TM, et al. Prospective and retrospective review of gynecologic cytopathology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference Working Group 2. Arch Pathol Lab Med. 2013;137:175-182.
18. Tworek J, Nayar R, Savaloja L, et al. General quality practices in gynecologic cytopathology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference Working Group 3. Arch Pathol Lab Med. 2013;137:190-198.
19. Zhao C, Chen X, Onisko A, et al. Follow-up outcomes for a large cohort of US women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. Gynecol Oncol. 2011;122:291-296.
20. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013;17:S56-S63.
21. Wright TC, Stoler MH, Sharma A, et al. Evaluation of HPV16 and HPV18 genotyping for triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136:578-586.